Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilotinib in Cerebellar Ataxia
NCT03932669Phase 2Completed
- Sponsor
- Seoul National University Hospital
- Start
- Nov 2018
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of nilotinib in spinocerebellar ataxia (SCA), sponsored by Seoul National University Hospital. Primary endpoint: Activity of Daily Living at 12 months. Started Nov 2018; status: completed.
02
Drugs
nilotinib
03
Conditions
spinocerebellar ataxia (SCA)
Beyond the preview
Go deeper on NCT03932669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03932669.